Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Polycystic Ovary Syndrome 2Pituitary Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Liposarcoma 1Diabetes Mellitus, Type 2 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 87Cisplatin 66Cystectomy 38pembrolizumab 34Docetaxel 25Nivolumab 24durvalumab 21Paclitaxel 19Magnetic Resonance Spectroscopy 18Radiotherapy 17Mitomycin 17Carboplatin 16atezolizumab 15Doxorubicin 14Cystoscopy 14BCG Vaccine 13Surveys and Questionnaires 12Standard of Care 12avelumab 11Sunitinib 10tremelimumab 9Transurethral Resection of Bladder 9Ipilimumab 9Filgrastim 9Blood Specimen Collection 9Specimen Handling 8Neoadjuvant Therapy 8Methotrexate 8Methods 8Early Intervention, Educational 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urinary Bladder Neoplasms × Rosiglitazone × Clear all
NCT00084578 2013-07-15

Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder

Fox Chase Cancer Center

Phase NA Withdrawn
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡